Novartis' Afinitor wins EU approval for breast cancer
This article was originally published in Scrip
The European Commission has approved Novartis' Afinitor (everolimus) to treat advanced breast cancer in combination with Pfizer's Aromasin (exemestane). The commission has granted approval in all 27 EU member states, Norway and Iceland.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.